The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|March 19, 2020
Lonza Pharma & Biotech
Author(s)Lonza Pharma & Biotech
At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable biotech and pharma companies to bring large and small-molecule medicines to patients in need.
At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable biotech and pharma companies to bring large and small-molecule medicines to patients in need. From drug substance to the final drug product, our solutions feature concept to commercial capabilities to simplify your outsourcing experience and to provide a reliable outcome when you expect it. Together, we can bring your next medicine to life.
Lonza Pharma & Biotech
Muechensteinstrasse 38 4002 Basel, Switzerland
tel. + 41.61.316 8111
solutions@lonza.com
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.